MX2015006195A - Procedimiento para preparar profarmacos de nucleosidos. - Google Patents

Procedimiento para preparar profarmacos de nucleosidos.

Info

Publication number
MX2015006195A
MX2015006195A MX2015006195A MX2015006195A MX2015006195A MX 2015006195 A MX2015006195 A MX 2015006195A MX 2015006195 A MX2015006195 A MX 2015006195A MX 2015006195 A MX2015006195 A MX 2015006195A MX 2015006195 A MX2015006195 A MX 2015006195A
Authority
MX
Mexico
Prior art keywords
nucleoside prodrugs
preparing nucleoside
preparing
prodrugs
phosphorochloridate
Prior art date
Application number
MX2015006195A
Other languages
English (en)
Inventor
Christopher Mcguigan
Fabrizio Pertusati
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015006195(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en
Priority claimed from GB201307314A external-priority patent/GB201307314D0/en
Application filed by Univ Cardiff filed Critical Univ Cardiff
Publication of MX2015006195A publication Critical patent/MX2015006195A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
    • H01S5/00—Semiconductor lasers
    • H01S5/30—Structure or shape of the active region; Materials used for the active region
    • H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
    • H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
    • H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un proceso para preparar fosforamidatos de nucleósidos, en dónde un anantiomero deseado, que tiene en cuenta el centro quiral asimétrico del atomo de fosforo P, se provee una cantidad enriquecida; el procedimiento comprende una sal de metal seleccionada del grupo que consiste de sales de Cu, Fe, La y Yb.
MX2015006195A 2012-11-16 2013-11-15 Procedimiento para preparar profarmacos de nucleosidos. MX2015006195A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1220666.0A GB201220666D0 (en) 2012-11-16 2012-11-16 Process for preparing chemical compounds
GB201307314A GB201307314D0 (en) 2013-04-23 2013-04-23 Process for preparing chemical compounds
PCT/GB2013/053018 WO2014076490A1 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs

Publications (1)

Publication Number Publication Date
MX2015006195A true MX2015006195A (es) 2015-12-08

Family

ID=49622844

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006195A MX2015006195A (es) 2012-11-16 2013-11-15 Procedimiento para preparar profarmacos de nucleosidos.

Country Status (28)

Country Link
US (3) US10005810B2 (es)
EP (3) EP3235824B1 (es)
JP (5) JP2016506371A (es)
KR (1) KR20150103669A (es)
CN (2) CN104903339A (es)
AU (1) AU2013346515B2 (es)
CA (1) CA2891266C (es)
CL (1) CL2015001307A1 (es)
CY (2) CY1119161T1 (es)
DK (2) DK3235824T3 (es)
EA (1) EA028871B1 (es)
ES (3) ES2725491T3 (es)
HK (1) HK1210784A1 (es)
HR (2) HRP20170791T1 (es)
HU (2) HUE033335T2 (es)
IL (1) IL238792A (es)
IN (1) IN2015DN04090A (es)
LT (2) LT3150616T (es)
MX (1) MX2015006195A (es)
MY (1) MY176133A (es)
NZ (1) NZ708177A (es)
PH (1) PH12015501090B1 (es)
PL (2) PL3150616T3 (es)
PT (2) PT3235824T (es)
RS (2) RS58849B1 (es)
SG (3) SG11201503750YA (es)
SI (2) SI3235824T1 (es)
WO (1) WO2014076490A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
RS58849B1 (sr) * 2012-11-16 2019-07-31 Univ College Cardiff Consultants Ltd Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
JP2017504572A (ja) * 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
WO2015198058A1 (en) * 2014-06-25 2015-12-30 Nucana Biomed Limited Gemcitabine prodrugs
CN106470672B (zh) 2014-06-25 2019-11-05 努卡那生物医药有限责任公司 包括吉西他滨前药的制剂
CN105254694B (zh) * 2014-07-14 2018-11-27 正大天晴药业集团股份有限公司 氘代核苷衍生物
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法
BR112017001847A2 (pt) * 2014-07-31 2018-02-27 Sandoz Ag processo para a preparação de um composto de fórmula (i), mistura, composição e composto de fórmula (ii)
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN105461774B (zh) * 2014-09-30 2020-11-24 江苏豪森药业集团有限公司 索非布韦的制备方法
CN105461773B (zh) * 2014-09-30 2020-12-01 江苏豪森药业集团有限公司 索非布韦的制备方法及其中间体
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
WO2016073756A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
AU2016229966B2 (en) 2015-03-06 2018-09-27 Atea Pharmaceuticals, Inc. Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10407456B2 (en) 2015-03-26 2019-09-10 Quimica Sintetica, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (zh) * 2015-07-28 2021-05-11 广东东阳光药业有限公司 一种改良的索菲布韦制备方法
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106539810B (zh) * 2015-09-16 2021-03-09 济南高合医疗科技有限公司 一种富集了nuc-1031单一异构体的组合物及其制备方法和用途
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
MX2018004137A (es) * 2015-10-05 2018-06-13 NuCana plc Terapia de combinacion.
WO2017090264A1 (ja) * 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
EP4011896A1 (en) * 2015-12-11 2022-06-15 NuCana plc Diastereoselective synthesis of (sp)-gemcitabine-[phenyl(benzoxy-l-alaninyl)]phosphate nuc-1031
GB201522771D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) * 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
CN107652342A (zh) * 2016-07-23 2018-02-02 江苏万高药业股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
DK3512863T3 (da) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
WO2018113652A1 (zh) * 2016-12-23 2018-06-28 四川科伦博泰生物医药股份有限公司 核苷磷酸类化合物及其制备方法和用途
KR102592899B1 (ko) 2017-02-01 2023-10-24 아테아 파마슈티컬즈, 인크. C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
JP2021521118A (ja) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド 肝硬変を伴うｈｃｖ感染患者の治療
WO2019237957A1 (zh) 2018-06-12 2019-12-19 四川科伦博泰生物医药股份有限公司 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
RU2740058C1 (ru) * 2020-06-26 2020-12-31 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения софосбувира и фосфорамидаты
CN112409431B (zh) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用
WO2024107859A1 (en) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
CA2317505C (en) 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
BR0307712A (pt) 2002-02-14 2005-05-24 Pharmasset Ltd Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
EP1928475B1 (en) * 2005-08-15 2018-05-23 Riboscience LLC Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
JP2012514657A (ja) 2009-01-09 2012-06-28 ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体
TWI576352B (zh) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
UY33312A (es) * 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
EP2596004B1 (en) * 2010-07-19 2014-09-10 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
CN105061534A (zh) * 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
EP2655392B1 (en) * 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
PL3447061T3 (pl) * 2011-03-01 2022-01-31 NuCana plc Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu
CN103635196B (zh) * 2011-03-02 2019-05-07 J·深塔格 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物、治疗方法和诊断方法
CA2852064A1 (en) * 2011-10-14 2013-04-18 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
RS58849B1 (sr) * 2012-11-16 2019-07-31 Univ College Cardiff Consultants Ltd Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
US9815864B2 (en) * 2013-06-26 2017-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HRP20220911T1 (hr) 2013-09-11 2022-10-28 Emory University Sastav nukleotida i nukleozida i njihova uporaba
AU2014331863C1 (en) * 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP2017504572A (ja) 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
US20170001988A1 (en) * 2013-11-27 2017-01-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Piperidine and piperazine derivatives and their use in treating viral infections and cancer
CN106470672B (zh) 2014-06-25 2019-11-05 努卡那生物医药有限责任公司 包括吉西他滨前药的制剂
WO2015198058A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Gemcitabine prodrugs
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
EP3197456B2 (en) 2015-05-14 2023-10-11 NuCana plc Cancer treatments
MX2018004137A (es) 2015-10-05 2018-06-13 NuCana plc Terapia de combinacion.
EP4011896A1 (en) 2015-12-11 2022-06-15 NuCana plc Diastereoselective synthesis of (sp)-gemcitabine-[phenyl(benzoxy-l-alaninyl)]phosphate nuc-1031
WO2017109444A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
WO2017109486A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
GB201713914D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy

Also Published As

Publication number Publication date
PH12015501090A1 (en) 2015-07-27
LT3235824T (lt) 2019-07-10
ES2618732T3 (es) 2017-06-22
PT3150616T (pt) 2017-06-09
SG10201510322UA (en) 2016-01-28
AU2013346515A1 (en) 2015-06-04
JP2023052536A (ja) 2023-04-11
JP2021020919A (ja) 2021-02-18
MY176133A (en) 2020-07-24
PL3150616T3 (pl) 2017-09-29
EP2920192B1 (en) 2017-02-22
SI3235824T1 (sl) 2019-08-30
NZ708177A (en) 2017-08-25
ES2627195T3 (es) 2017-07-27
US20150291650A1 (en) 2015-10-15
JP7519259B2 (ja) 2024-07-19
CA2891266C (en) 2020-12-08
CY1121663T1 (el) 2020-07-31
CN104903339A (zh) 2015-09-09
PT3235824T (pt) 2019-05-30
IN2015DN04090A (es) 2015-10-09
HUE044605T2 (hu) 2019-11-28
CL2015001307A1 (es) 2015-12-11
US20220033433A1 (en) 2022-02-03
EP3150616A1 (en) 2017-04-05
WO2014076490A1 (en) 2014-05-22
HK1210784A1 (en) 2016-05-06
DK3150616T3 (en) 2017-06-06
HRP20170791T1 (hr) 2017-08-25
DK3235824T3 (da) 2019-05-20
SG10201510324YA (en) 2016-01-28
JP2019196360A (ja) 2019-11-14
PL3235824T3 (pl) 2019-09-30
HRP20190831T1 (hr) 2019-08-23
RS56038B1 (sr) 2017-09-29
SI3150616T1 (sl) 2017-08-31
LT3150616T (lt) 2017-07-25
HUE033335T2 (en) 2017-11-28
ES2725491T3 (es) 2019-09-24
KR20150103669A (ko) 2015-09-11
IL238792A0 (en) 2015-06-30
CA2891266A1 (en) 2014-05-22
JP2018009000A (ja) 2018-01-18
CN111592577A (zh) 2020-08-28
RS58849B1 (sr) 2019-07-31
CY1119161T1 (el) 2018-02-14
US11040997B2 (en) 2021-06-22
EP3150616B1 (en) 2017-05-10
EP3235824A1 (en) 2017-10-25
EA028871B1 (ru) 2018-01-31
IL238792A (en) 2017-09-28
US20180273575A1 (en) 2018-09-27
AU2013346515B2 (en) 2017-05-25
EA201590955A1 (ru) 2015-08-31
US10005810B2 (en) 2018-06-26
SG11201503750YA (en) 2015-06-29
EP2920192A1 (en) 2015-09-23
PH12015501090B1 (en) 2015-07-27
BR112015011155A2 (pt) 2017-07-11
EP3235824B1 (en) 2019-03-27
JP2016506371A (ja) 2016-03-03

Similar Documents

Publication Publication Date Title
PH12015501090A1 (en) Process for preparing nucleoside prodrugs
HK1256856A1 (zh) 用於抗病毒治療的2'-取代的卡巴-核苷類似物
CL2011000718A1 (es) Proceso para la preparacion de compuestos fosforados enantiomericos.
IL228680A0 (en) Analogues of n nucleoside pyrimidine 1' - converted to antiviral therapy
EP2796555A4 (en) METHOD FOR PRODUCING L-LYSINE WITH MICROORGANISMS COMPETITIVE FOR THE PREPARATION OF L-LYSINE
SI2681227T1 (sl) Fosforamidatni derivati 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka
EP2674395A4 (en) PROCESS FOR THE PRODUCTION OF FLUOROSULFONYLIMIDE AMMONIUM SALT
IL232843A0 (en) 4'-azido', 3'-fluoro modified nucleoside derivatives as inhibitors of hepatitis C virus RNA replication
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
MX2012000583A (es) Procedimiento para la preparacion de derivados de 3-triazolil-sulfoxido quirales.
BR112015006874A2 (pt) ligantes de rig-i inovadores e métodos para produzir os mesmos
SG11201401523QA (en) Process for producing phosphorus modified zeolite catalysts
TN2013000369A1 (en) Preventing or reducing scale in wet-process phosphoric acid production
IL235922A0 (en) Production of ammonium phosphates
PL2714589T3 (pl) Dwuwodzianowo-półwodzianowy sposób wytwarzania kwasu fosforowego
EP2834190A4 (en) PROCESS FOR PREPARING HYPOPHOSPHITE SALTS
HK1199004A1 (en) Process for stabilizing heat exchanger tubes in andrussow process andrussow
EP2845859A4 (en) PROCESS FOR THE PREPARATION OF AMMONIUM SALT OF FOSFOMYCIN
RS56101B1 (sr) 4'-azido-3'-fluoro supstituisani derivati nukleozida kao inhibitori hcv rnk replikacije
JO3153B1 (ar) منع أو اختزال القشور عند إنتاج حمض الفوسفوريك بالمعالجة الرطبة
TH134009B (th) จุลินทรีย์ผลิตโอ-ฟอสโฟเซรีน (o-phosphoserine) และวิธีการผลิตแอล-ซิสเทน (L-cysteine) หรืออนุพันธ์ของ แอล-ซิสเทนจากโอ-ฟอสโฟเซรีน (o-phosphoserine) โดยการใช้จุลินทรีย์เดียวกัน

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: NUCANA PLC

HC Change of company name or juridical status

Owner name: NUCANA PLC